It's been a banner year so far for Insmed Inc. (INSM), with its shares having more than doubled, thanks to Arikayce's surging sales, Brensocatib's ASPEN study success, and TPIP's promising phase II results.
Arikayce, the company's marketed drug, is an antibacterial drug, which secured accelerated approval from the FDA in Sep.2018, for the treatment of a serious lung disease caused by a group of bacteria, Mycobacterium avium complex, in adults who have limited or no alternative treatment options.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.